Final Rule Now?
Exclusivity incentive appears to be working as have received more than 100 Proposed Pediatric Study Requests, so why now?
Certain limitations on scope and effect of the exclusivity offered by FDAMA …significant gaps in pediatric labeling
- most antibiotics, biologics, off-patent drugs, older drug products on which there is no existing exclusivity